# Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

> **NCT06127407** · PHASE3 · RECRUITING · sponsor: **Servier Bio-Innovation LLC** · enrollment: 136 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

## Interventions

- **DRUG:** Ivosidenib 500mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06127407
- **Lead sponsor:** Servier Bio-Innovation LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-09
- **Primary completion:** 2028-02-01
- **Final completion:** 2030-11-26
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06127407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06127407, "Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06127407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*